Kazia Therapeutics Achieves Breakthrough in Triple-Negative Breast Cancer Treatment with Paxalisib

Kazia Therapeutics Reports Encouraging Breakthrough in Triple-Negative Breast Cancer Treatment

Kazia Therapeutics Limited, an oncology-focused drug development company, announces a significant advancement in the treatment of stage IV triple-negative breast cancer (TNBC). A patient enrolled in a combination therapy involving paxalisib, pembrolizumab (Keytruda®), and standard chemotherapy achieves an initial immune-complete response (iCR) as per iRECIST criteria. This remarkable outcome underscores the potential of this combination therapy in treating an aggressive cancer subtype known for its poor prognosis and limited treatment options. The achievement follows an earlier report detailing an 86% reduction in tumor burden within just three weeks of treatment, showcasing the promising efficacy of the therapy.

The complete metabolic resolution of all previously identified lesions, as confirmed by a subsequent PET/CT scan, further validates the initial immune-complete response. In the context of stage IV metastatic TNBC, where complete responses are exceptionally rare, the results from this case are groundbreaking. Existing treatments like pembrolizumab monotherapy have shown response rates ranging from only 0.6% to 4%, while other approved agents achieve similarly low rates of around 2% to 4%. The extraordinary finding of an immune-complete response prior to confirmatory imaging not only challenges historical benchmarks but also suggests that this combination regimen may significantly enhance biological activity against the disease.

Dr. John Friend, CEO of Kazia Therapeutics, emphasizes the encouraging nature of these findings, aligning with the company's hypothesis that paxalisib may enhance anti-tumor immunity when combined with checkpoint blockade therapies like pembrolizumab. This successful case adds momentum to Kazia's ongoing Phase 1b program focused on advanced breast cancer and aligns with the company's broader strategic advancements in its drug development pipeline. The company is keen to leverage this breakthrough as it prepares for upcoming scientific presentations at the Brisbane Cancer Conference, scheduled for November 27-28, 2025, which will further enhance its visibility in the oncology community.

In addition to the breakthrough, Kazia Therapeutics continues to make strides in its clinical endeavors, indicating robust engagement with ongoing research in oncology. The company’s focus on innovative therapies like paxalisib underscores its commitment to addressing unmet medical needs in cancer treatment, particularly in challenging areas like TNBC. As they advance their research and clinical programs, the implications of these findings could pave the way for new treatment paradigms in oncology.